Omeros Corporation (OMER)

Omeros Corp. experienced several significant stock events in the past six months. The company reported a net loss of $30.9 million for Q3 2025. An anticipated agreement with Novo Nordisk for zaltenibart is expected to provide a $240 million upfront cash payment. The FDA approved YARTEMLEA for TA-TMA in December 2025. Omeros reported an earnings per share (EPS) of ($0.19), beating analysts' consensus estimates of ($0.58) in Q3 2025. Analysts have revised price targets for OMER. Short interest in Omeros Corporation saw a significant jump of 24.0% as of January 15, 2026. In January 2026, CAO David J. Borges sold 30,000 shares of the company's stock. The share price as of February 6, 2026, was $11.23, representing an increase of 29.83% over the price on February 7, 2025.

Omeros Corporation's product and service demand is not typically subject to the same kind of seasonality as consumer goods. Demand for its products is driven by disease prevalence, treatment guidelines, and market access. The company's revenue from OMIDRIA royalties has shown some quarterly fluctuations but is generally declining year-over-year. The primary drivers for the company's financial performance and market interest are clinical trial progress, regulatory approvals, and strategic partnerships.

Omeros Corporation is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on discovering, developing, and commercializing small-molecule and protein therapeutics for orphan indications and diseases related to inflammation, complement-mediated disorders, cancers, and addictive and compulsive disorders. Its lead product candidate, narsoplimab, has completed pivotal studies for HSCT-TMA and is in Phase III trials for IgAN and Phase II trials for COVID-19 and ARDS. The FDA approved YARTEMLEA (narsoplimab) as the first therapy for TA-TMA in December 2025. Zaltenibart, an investigational inhibitor of MASP-3, has shown positive data in a Phase 2 study for PNH and is in Phase 3 trials for PNH and Phase 2 trials for other alternative pathway disorders. Other pipeline products include OMS1029, OMS527, OMS405, and several preclinical programs targeting various diseases.

Omeros Corporation is headquartered in Seattle, Washington, United States. The company emphasizes a diverse team from "all corners of the globe," suggesting a global talent pool for its research and development efforts.

Omeros' brand reputation has been significantly bolstered by the FDA approval of YARTEMLEA for TA-TMA in December 2025. This approval validates its research and development efforts. The company faced setbacks, including an FDA rejection of narsoplimab in 2021. Omeros positions itself as an innovative company focused on developing "first-in-class drugs with new mechanisms of action that target previously untapped receptors and enzymes" for challenging diseases. The anticipated significant upfront payment from the Novo Nordisk transaction also contributes positively to its financial standing and perceived stability.

Omeros Corporation has a significant institutional ownership presence, with 220 institutional owners and shareholders holding a total of 37,750,328 shares. Major institutional shareholders include BlackRock, Inc., Ingalls & Snyder Llc, and Vanguard Group Inc. Institutional investors hold approximately 49.46% of the common stock, while insiders hold about 3.77%. Key individual owners and insiders include Dr. Gregory A. Demopulos, Dr. Peter A. Demopulos, and Dr. Leroy E. Hood.